ID   FTO 9.1
AC   CVCL_E6IT
SY   FTO9.1
RX   PubMed=9918938;
CC   Virology: Susceptible to hepatitis B virus (HBV) infection (PubMed=9918938).
CC   Selected for resistance to: ChEBI; CHEBI_472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; BrdU; BUdR).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:543; ANXA5.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
CC   Breed/subspecies: AxC; RS=RS_0000369.
DI   NCIt; C60416; Rat hepatocellular carcinoma
OX   NCBI_TaxID=10116; ! Rattus norvegicus (Rat)
HI   CVCL_5124 ! FTO-2B
SX   Male
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=9918938; DOI=10.1002/hep.510290238;
RA   Gong Z.-J., De Meyer S., van Pelt J.F., Hertogs K., Depla E.,
RA   Soumillion A., Fevery J., Yap S.H.;
RT   "Transfection of a rat hepatoma cell line with a construct expressing
RT   human liver annexin V confers susceptibility to hepatitis B virus
RT   infection.";
RL   Hepatology 29:576-584(1999).
//